Bio-Hermes-002
10 Tampa Bay: Tampa researcher wants to study your brain, detect early signs of Alzheimer’s
The free clinical trial at Axiom Brain Health in Tampa works to detect early signs of Alzheimer’s and other cognitive diseases, even years before symptoms appear. Author: Hannah Dineen Published: 4:04 PM EST March 6, 2025 Updated: 8:52 PM EST March 6, 2025 TAMPA, Fla. — It’s estimated nearly 7 million people in the U.S. are living with Alzheimer’s disease. […]
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration with Roche for the Transformative Bio-Hermes-002 Study
Washington D.C., Feb. 18, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Roche to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images as well as numerous races and ethnicities […]
Beckman Coulter Diagnostics Joins the Transformative Bio-Hermes-002 Study as New Partner
Washington D.C., Jan. 23, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Beckman Coulter Diagnostics as a strategic partner in the Bio-Hermes-002 study. This first-time collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images […]
Senior Housing News: Eli Lilly Partners with the Global Alzheimer’s Platform Foundation on Blood Test Study
By Austin Montgomery| December 11, 2024 Global Alzheimer’s Platform Foundation (GAP) has partnered with Eli Lilly and Company (NYSE: LLY) for a study comparing blood tests that could help predict and diagnose Alzheimer’s disease. The Bio-Hermes-002 study looks to increase participation of underrepresented older adults within typical Alzheimer’s clinical research, with at least 25% participation earmarked […]
Investors Hangout: Collaboration to Enhance Alzheimer’s Research with Eli Lilly Strategic Partnership in Alzheimer’s Research
The Global Alzheimer’s Platform Foundation (GAP) is excited to announce its collaboration with Eli Lilly and Company on the transformative Bio-Hermes-002 study. This partnership is poised to broaden the understanding of Alzheimer’s disease by integrating advanced biomarkers that may assist in its early detection and diagnosis. Significance of the Bio-Hermes-002 Study Like its predecessor, Bio-Hermes-001, […]
AP: ViewMind Joins Bio-Hermes-002 Landmark Study in Partnership with Global Alzheimer’s Platform Foundation
ViewMind Precision Neurological Assessments ViewMind Digital BiomarkerPublished 7:31 AM EST, December 10, 2024Share To Enhance Alzheimer’s Diagnosis Through Diverse Biomarker Analysis “We expect ViewMind’s promising technology to offer the field alternative methods for detecting and diagnosing Alzheimer’s disease.”— John Dwyer, President of the Global Alzheimer’s Platform Foundation NEW YORK CITY, NY, UNITED STATES, December 10, […]
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration with Eli Lilly and Company for the Transformative Bio-Hermes-002 Study
Washington D.C., Dec. 9, 2024 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Eli Lilly and Company (Lilly) to the Bio-Hermes-002 study. This collaboration will enrich the unique, observational platform study that compares blood-based and digital biomarkers across a broad range of races and ethnicities that may help predict and diagnose Alzheimer’s […]
Contify Life Sciences: Cognivue to Partner on Another Major Clinical Study with the Global Alzheimer’s Platform Foundation
Contify Life Science News Nov 3 • 11:52 PM *Cognivue’s participation in the study will help predict underlying AD pathologies and analyze MRI, neuroinflammation, and longitudinal data. Oct. 30– Cognivue issued the following news release:. Its proven ability to distinguish between cognitively normal individuals, those with MCI, and mild dementia— regardless of amyloid status., Validated […]
Precision Medicine Online: GAP Foundation Launches Second Study on Alzheimer’s Blood Biomarkers
Oct 30, 2024 | staff reporterSave for later NEW YORK – The Global Alzheimer’s Platform (GAP) Foundation has launched the Bio-Hermes-002 study, in which it will continue to explore biomarkers that can predict the likelihood that a patient has amyloid and tau accumulations in their brains, signaling a potential Alzheimer’s diagnosis. The Alzheimer’s research-focused nonprofit announced the […]
Collaborative effort to conduct a study aimed at improving the diagnosis of Alzheimer’s and related dementias for everyone
Global Alzheimer’s Platform Foundation Announces Strategic Partnerships for the Transformative Bio-Hermes-002 Study Washington D.C., Oct. 28, 2024 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome the initial strategic partners in the Bio-Hermes-002 study. These collaborations will enhance the unique, observational platform study that compares blood-based and digital biomarkers across a broad range […]